Krystal Biotech (KRYS) Settles with PeriphaGen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Krystal Biotech Announces Settlement with PeriphaGen, Inc.
March 15, 2022 7:00 AM EDTPITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (Krystal) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding term sheet with PeriphaGen, Inc. (PeriphaGen) to resolve all claims in the trade secret litigation filed by PeriphaGen on May 20, 2020.
Under the conditions of the term sheet, which are legally binding, Krystal will receive... More
